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Deletion of Abca7 increases cerebral amyloid-β accumulation in the J20 mouse 
model of Alzheimer's disease 
Abstract 
ATP-binding cassette transporter A7 (ABCA7) is expressed in the brain and has been detected in 
macrophages, microglia, and neurons. ABCA7 promotes efflux of lipids from cells to apolipoproteins and 
can also regulate phagocytosis and modulate processing of amyloid precursor protein (APP) to generate 
the Alzheimer's disease (AD) amyloid-β (Aβ) peptide. Genome-wide association studies have indicated 
that ABCA7 single nucleotide polymorphisms confer increased risk for late-onset AD; however, the role 
that ABCA7 plays in the brain in the AD context is unknown. In the present study, we crossed 
ABCA7-deficient (A7-/-) mice with J20 amyloidogenic mice to address this issue. We show that ABCA7 
loss doubled insoluble Aβ levels and thioflavine-S-positive plaques in the brain. This was not related to 
changes in APP processing (assessed by analysis of full-length APP and the APP β C-terminal fragment). 
Apolipoprotein E regulates cerebral Aβ homeostasis and plaque load; however, the apolipoprotein E 
concentration was not altered by ABCA7 loss. Spatial reference memory was significantly impaired in 
both J20 and J20/A7-/- mice compared with wild-type mice; however, there were no cognitive differences 
between J20 and J20/A7-/- mice. There were also no major differences detected in hippocampal or 
plaqueassociated microglial/macrophage markers between J20 and J20/A7-/- mice, whereas the 
capacity for bone marrow-derived macrophages derived from A7-/- mice to take up oligomeric Aβ was 
reduced by 51% compared with wild-type mice. Our results suggest that ABCA7 plays a role in the 
regulation of Aβ homeostasis in the brain and that this may be related to altered phagocyte function. 
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Neurobiology of Disease
Deletion of Abca7 Increases Cerebral Amyloid-
Accumulation in the J20 Mouse Model of Alzheimer’s
Disease
Woojin S. Kim,1,2* Hongyun Li,3,4* Kalani Ruberu,3,4 Sharon Chan,1,2 David A. Elliott,1,2,3 Jac Kee Low,1 David Cheng,1,2
Tim Karl,1,2,5 and Brett Garner3,4
1Neuroscience Research Australia, Randwick, New South Wales 2031, Australia, 2School of Medical Sciences, University of New South Wales, Sydney, New
South Wales 2052, Australia, 3Illawarra Health and Medical Research Institute and 4School of Biological Sciences, University of Wollongong, New South
Wales 2522, Australia, and 5Schizophrenia Research Institute, Darlinghurst, New South Wales 2010, Australia
ATP-binding cassette transporter A7 (ABCA7) is expressed in the brain and has been detected in macrophages, microglia, and neurons.
ABCA7 promotes efflux of lipids from cells to apolipoproteins and can also regulate phagocytosis and modulate processing of amyloid
precursor protein (APP) to generate the Alzheimer’s disease (AD) amyloid- (A) peptide. Genome-wide association studies have
indicated that ABCA7 single nucleotide polymorphisms confer increased risk for late-onset AD; however, the role that ABCA7 plays in the
brain in the AD context is unknown. In the present study, we crossed ABCA7-deficient (A7 /) mice with J20 amyloidogenic mice to
address this issue. We show that ABCA7 loss doubled insoluble A levels and thioflavine-S–positive plaques in the brain. This was not
related to changes in APP processing (assessed by analysis of full-length APP and the APP  C-terminal fragment). Apolipoprotein E
regulates cerebral A homeostasis and plaque load; however, the apolipoprotein E concentration was not altered by ABCA7 loss. Spatial
reference memory was significantly impaired in both J20 and J20/A7 / mice compared with wild-type mice; however, there were no
cognitive differences between J20 and J20/A7 / mice. There were also no major differences detected in hippocampal or plaque-
associated microglial/macrophage markers between J20 and J20/A7 / mice, whereas the capacity for bone marrow-derived macro-
phages derived from A7 / mice to take up oligomeric A was reduced by 51% compared with wild-type mice. Our results suggest that
ABCA7 plays a role in the regulation of A homeostasis in the brain and that this may be related to altered phagocyte function.
Introduction
Genome-wide association studies indicate that ATP-binding
cassette transporter A7 (ABCA7 ) is a genetic risk factor for
late-onset Alzheimer’s disease (AD) (Harold et al., 2009; Hol-
lingworth et al., 2011). ABCA7 is a member of the “A” subfamily
of ABC transporters that predominantly transport lipids and
other lipophilic molecules across membranes (Kim et al., 2008).
Cell-culture studies suggest that, similar to its closest homolog,
ABCA1 (54% sequence identity), ABCA7 facilitates the transport
of phospholipids and, to a lesser extent, cholesterol, across cell
membranes to extracellular apolipoprotein A–I (apoA–I) and
apolipoprotein E (apoE) discoidal lipoprotein complexes (Wang
et al., 2003; Abe-Dohmae et al., 2004; Chan et al., 2008). Overex-
pression of ABCA1 or ABCA7 in cell lines that constitutively
express human amyloid precursor protein (APP) results in de-
creased extracellular levels of amyloid- (A) peptide (Sun et al.,
2003; Kim et al., 2007; Chan et al., 2008). However, it is unclear
whether this anti-amyloidogenic action is linked to lipid trans-
port, because loss-of-function mutations in ABCA1 do not in-
hibit its capacity to downregulate A levels in vitro (Kim et al.,
2010).
In addition to its similarity to ABCA1, ABCA7 also shares a
high degree of sequence homology (24% identity, 43% similarity)
with the Caenorhabditis elegans gene CED-7 (Jehle et al., 2006).
CED-7 plays a crucial role in phagocytosis and it is now recog-
nized that ABCA7 also regulates phagocytosis in several mamma-
lian cell types (Iwamoto et al., 2006; Jehle et al., 2006). These
findings are consistent with the high expression of ABCA7 in
human phagocytes, including macrophages and, in particular,
microglia (Kaminski et al., 2000; Kim et al., 2006). Although
ABCA7 is highly expressed in the brain (Wang et al., 2003; Kim et
al., 2005; Kim et al., 2008), its function in the context of AD is
unknown. Previous studies have used amyloidogenic AD mouse
models to examine the impact that Abca1 deletion has on the
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regulation of cerebral A homeostasis, amyloid plaque burden,
and associated neuropathological and behavioral parameters
(Hirsch-Reinshagen et al., 2005; Koldamova et al., 2005; Wahrle
et al., 2005; Lefterov et al., 2009). In the present study, we have
undertaken an in vivo assessment of the role that ABCA7 plays in
the AD context and provide evidence that Abca7 deletion in-
creases cerebral A accumulation.
Materials and Methods
Transgenic mice. Hemizygous hAPPSwInd J20 mice and Abca7
/  mice
(all of the C57BL/6J background and backcrossed 10 generations) were
crossed to generate J20/Abca7/  breeders. These mice were mated to
generate J20/Abca7/ and J20/Abca7/  mice (“J20” and “J20/A7/,”
respectively). Wild-type (WT) mice were used as controls for spatial
memory testing. The generation and genotyping of the J20 and
Abca7 /  mice has been described previously (Mucke et al., 2000; Kim
et al., 2005). Test animals were males at 17 months of age (J20, n  14,
528  4 d old; J20/A7 /, n  11, 528  12 d old; WT, n  9, 447  40 d
old). Ethics approval was acquired from the University of New South
Wales and the University of Wollongong animal ethics committees.
Spatial reference memory assessment using the cheeseboard paradigm.
The cheeseboard paradigm is established as a “dry-land” equivalent of
the Morris water maze to assess spatial reference memory in male J20
mice (Karl et al., 2012). Testing was performed with a 9 d training period
(3 2 min trials per day) during which the latency to find a food reward was
measured. On the test day, a probe trial was conducted and the percent-
age time spent in the target zone was calculated. Male Abca7 / mice
performed the same as WT mice in the cheeseboard paradigm and were
therefore not tested as an additional control group in the present study
(Logge et al., 2012).
Tissue preparation. Euthanized mice were perfused with PBS. The
brains were sagittally divided; the right hemisphere was snap frozen and
stored at 80°C and the left hemisphere was fixed in 4% paraformalde-
hyde. Cryosections were collected and stored at 20°C in antifreeze
solution. Frozen brain tissue (30 –50 mg) was homogenized in 8 volumes
of 140 mM NaCl, 3 mM KCl, 25 mM Tris, pH 7.4, containing 1% Nonidet
P-40 and Roche complete protease inhibitors (TBS/NP40 extraction buf-
fer) using a Precellys 24 homogenizer (2  30 s, 6000  g). Homogenates
were centrifuged at 20,817  g for 15 min at 4°C and the supernatant
(TBS/NP40-soluble fraction) was stored at 80°C until use. The pellet
was homogenized with 6 volumes of 6.25 M guanidine HCl (gHCl) in 50
mM Tris, pH 8.0, incubated for 4 h at 25°C, and centrifuged at 20,817 
g for 20 min at 4°C. The resultant supernatant was collected as the gHCl-
soluble fraction and stored at 80°C until use. Where specifically indi-
cated, hemibrains were dissected into hippocampus, cortex, and
cerebellum and homogenized in TBS without Nonidet P-40 as above
(Precellys 24 homogenizer, 2  30 s, 6000  g), the homogenates were
centrifuged at 20,817  g for 15 min at 4°C, and the supernatant (TBS-
soluble fraction) was stored at 80°C until use specifically for apoE
quantification by Western blotting. Protein was measured using the bi-
cinchoninic acid method.
A ELISA. A40 and A42 in TBS/NP40-soluble and gHCl-soluble
fractions of brain homogenates were quantified using the Beta Amyloid
x-40 and x-42 ELISA kits (Covance) as described previously (Elliott et al.,
2011).
Histology and immunohistochemistry. Sagittal sections (45 m thick,
free floating) were rinsed with TBS to remove cryoprotectants. The sec-
tions were then immersed in distilled H2O (2 min) followed by Harris
hemotoxylin (2 min), distilled H2O (3 min), 1% (w/v) thioflavine S (ThS,
Sigma T1892, 3 min), distilled H2O (3 min), 1% (v/v) acetic acid (20
min), distilled H2O (3 min), and mounted in buffered glycerol. Three
sections per mouse were analyzed from the hippocampal region between
lateral 1 mm to lateral 2 mm from the midline as defined using a mouse
brain atlas (Franklin and Paxinos, 2007). Images were captured using a
Nikon TE2000 microscope equipped with a SPOT digital camera (Diag-
nostic Instruments) and Image-Pro Plus 6.1 software (Media Cybernet-
ics). Analysis of whole ThS-stained sagittal sections indicated that plaque
deposition was predominantly within the hippocampus, with only occa-
sional plaques present in the cortex. ThS-positive plaques in the hip-
pocampus were therefore counted and expressed as the number of
plaques per section. For the purposes of comparison, hippocampal ThS-
positive plaque load was also expressed as the percentage coverage of the
area of interest (measured as square micrometers) using ImageJ software.
For immunohistochemistry, sections were stained using rabbit anti-
Iba1 (1:5000; Wako) or rat anti-Mac2 (1:2000; Cedarlane) for 16 h at 4°C,
followed by incubation with biotinylated secondary antibodies (1:2000;
Sigma or Jackson ImmunoResearch) for 2 h at 22°C, and streptavidin-
HRP (1:4000; Sigma) for 1 h at 22°C. The sections were developed using
DAB substrate (Vector Laboratories) and scanned at 20 magnification
(Aperio Digital Pathology System, Aperio Technologies). For quantifica-
tion, the percentage of pixels above background staining and the occu-
pied area (in square micrometers) of the positive staining within the
hippocampus was measured using ImageJ software. For triple-label im-
munofluorescence staining, the sections were incubated in primary an-
tibodies (1:2000 Iba1, 1:1000 Mac2, and 1:5000 6E10-Biotin) for 24 h at
4°C, and incubated with corresponding fluorescently labeled secondary
antibodies (Alexa Fluor 488 –anti-rat, Alexa Fluor 568 –streptavidin, and
Alexa Fluor 647–anti-rabbit, all at 1:500) at 22°C for 2 h. The sections
were mounted with antifade medium and visualized using a Leica SP5X
confocal microscope.
Western blotting. TBS/NP40-soluble (and, where specifically indicated,
TBS-soluble) homogenate fractions were analyzed by SDS-PAGE (15 g
of protein per lane) and Western blotting using antibodies to: ABCA1
(1:2000; Life Research), ABCA7 (1:5000; LifeSpan Bioscience), low-
density lipoprotein receptor (LDLR, 1:1000; Novus), apoE (1:5000; Cal-
biochem), WO2 (1:200; provided by Dr. Qiao-Xin Li and Prof. Colin
Masters, University of Melbourne), synaptophysin (1:10,000; Sigma),
PSD95 (1:1000; Invitrogen), APP C-terminal (1:10,000; Sigma), Iba1
(1:5000; Wako), Mac2 (1:2000; Cedarlane), and -actin (1:10,000;
Sigma). Signals were detected using species-specific HRP-conjugated
secondary antibodies and enhanced chemiluminescence and quantified
using ImageJ software. Integrated optical density data were normalized
to -actin levels and expressed as relative values.
Macrophage isolation and A uptake. Bone marrow-derived macro-
phages were obtained from five WT and five Abca7 /  mice as described
previously (Elliott et al., 2008). Based on previous studies of phagocytic
uptake of apoptotic cellular debris by Abca7/  macrophages (Jehle et
al., 2006), uptake of A oligomers from culture media was assessed after
45 min. A oligomers were prepared by sonicating human A42 (100 M
in Ham’s F12 cell culture medium) for 10 min, followed by 48 h of
incubation at 10°C.
Statistical analysis. For cognitive assessment, a one-way ANOVA was
used to analyze effects over training days and a one-way ANOVA fol-
lowed by Fisher-PLSD post hoc analysis was used to analyze memory
retention in the probe trial. Biochemical and histopathological data were
compared using the t test. Differences were regarded as significant if p 
0.05. All data are presented as means  SE.
Results
Deletion of ABCA7 increases insoluble A levels and ThS-
positive plaque load
To assess whether ABCA7 regulates pathways involved in AD, we
generated amyloidogenic J20 mice that lack ABCA7 (J20/A7/)
and compared these with their J20 littermates. Deletion of
ABCA7 resulted in significant 2.1-fold and 2.3-fold increases in
A42 and A40 levels, respectively, in the insoluble fractions of
brain homogenates (Fig. 1A). We also observed a nonsignificant
trend for increased soluble A42 and A40 levels in the J20/
A7/ mice (Fig. 1B). In the present study, ThS-positive amyloid
plaques were largely restricted to the hippocampus. Consistent
with the increased insoluble A detected by ELISA in the
hemibrain homogenates (which include the hippocampus),
the number of ThS-positive amyloid plaques detected in the
hippocampus was increased by 53% in the absence of ABCA7
(Fig. 1C,D). When hippocampal ThS-positive plaque load was
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expressed as a percentage relative to tissue area, we also observed
a significant 40% increase in the absence of ABCA7 (0.48  0.04
vs 0.67  0.06, mean  SE; J20 vs J20/A7/, respectively, p 
0.016). Note that the A42 concentration in the insoluble brain
fractions was 200 times higher than A40, whereas the levels
of these two A species were similar in the soluble fractions
(Fig. 1 A, B).
Spatial reference memory assessment
To assess whether increased amyloid deposition in the J20/A7/
mice is correlated with changes in spatial memory, mice were
tested using the cheeseboard paradigm (Karl et al., 2012). When
the animals were assessed by one-way ANOVA for their ability to
learn to find a food reward over a 9 d period, only the WT mice
were successful in this task (p  0.0003; Fig. 2A). Task acquisition
was impaired in both the J20 and J20/A7/ mice (p  0.4022
and p  0.1850, respectively; Fig. 2A). The cognitive performance
of J20/A7/ mice during training was the same as that of J20
mice (Fig. 2A). In the probe trial testing spatial memory, a signif-
icant effect (p  0.05) of genotype was detected when the three
groups were compared using ANOVA (Fig. 2B). Post hoc analysis
indicated that both the J20 and J20/A7/ mice showed impaired
memory retention compared with the WT animals. The spatial
memory of J20/A7 / mice was similar to that of J20 mice
(Fig. 2B).
We also assessed the J20 and J20/A7/ mice in additional
behavioral paradigms including a novel object recognition
task, the Y-maze (short-term recognition), and a fear condi-
tioning paradigm. We have previously validated each of these
tests in the J20 mouse model (Karl et al., 2012). However, these
tests did not reveal any differences between the J20 and J20/
A7 / mice (J. Low, D. Cheng, B. Garner, and T. Karl, unpub-
lished observations).
ABCA7 deletion does not alter APP
processing or apoE level
The increase in insoluble A and ThS-
positive plaque load associated with ABCA7
deletion (Fig. 1) may be due to altered APP
processing or decreased A clearance/deg-
radation. ABCA7 overexpression inhibits
processing of APP to form A in vitro (Chan
et al., 2008). Therefore, we assessed whether
ABCA7 deletion had any impact on full-
length APP and the  C-terminal fragment
(CTF) that is generated subsequent to
-secretase cleavage of APP. Neither APP
nor CTF levels were altered (Fig. 3), sug-
gesting that amyloidogenic processing of
APP is not accelerated by ABCA7 deletion.
ApoE binds to A in an isoform-
dependent manner and is thought to reg-
ulate A degradation and clearance from
the brain (LaDu et al., 1994; Jiang et al.,
2008; Castellano et al., 2011; Kim et al.,
2011; Bien-Ly et al., 2012; Cramer et
al., 2012). ABCA1 deletion in AD mouse
models is associated with significant
(70 –75%) reductions in apoE levels
(Hirsch-Reinshagen et al., 2005; Kol-
damova et al., 2005; Wahrle et al., 2005)
depending on the mouse model and age.
This is thought to be due to the impaired
capacity for apoE to receive its full com-
plement of lipids in the absence of ABCA1. Because ABCA7 also
promotes apoE lipidation in vitro (Chan et al., 2008), we mea-
sured apoE levels in the present study. There was no effect of
ABCA7 deletion on cerebral apoE levels (Fig. 3). Because both
ABCA1 and the LDLR influence apoE lipidation and recycling
(Zhou et al., 2008; Kim et al., 2011), we assessed the expression of
these proteins to determine their potential compensatory up-
regulation in J20/A7/ mice. Neither ABCA1 nor LDLR expres-
sion was altered by ABCA7 deletion (Fig. 3). As a surrogate
marker for neurodegeneration and synapse loss, the levels of syn-
aptophysin and PSD95 were measured. Synaptophysin levels
were not altered by ABCA7 deletion; however, we detected a
strong trend (p  0.05) for decreased PSD95, indicating that
ABCA7 deletion has a minor impact on neurodegeneration in J20
mice (Fig. 3).
In previous studies showing that ABCA1 deletion was associ-
ated with significant reductions in cerebral apoE levels in amy-
loidogenic mice, the “soluble” apoE fractions were either derived
from homogenates that contained detergent (0.25% SDS and 1%
Triton X-100 (Koldamova et al., 2005), similar to the conditions
used to generate the TBS/NP40-soluble fractions analyzed as in
Figure 3, or they were derived from homogenates that contained
either PBS (Hirsch-Reinshagen et al., 2005) or carbonate buffer
(Wahrle et al., 2005) in the absence of detergent. In addition, in
two of these studies (Hirsch-Reinshagen et al., 2005; Wahrle et
al., 2005), the hippocampus and remaining cortex were analyzed
separately for apoE. So that our data could be compared more
directly with these previous reports, we dissected the hippocam-
pal, cortical, and cerebellar regions from the brain and homoge-
nized them in TBS without detergents. These TBS-soluble
fractions were then analyzed by Western blotting for apoE. The
data reveal that apoE levels differed significantly depending on
the brain region (cortex  hippocampus  cerebellum), and we
Figure 1. Deletion of ABCA7 increases insoluble A and ThS plaques in J20 mice. A, B, The gHCL-soluble “Insoluble” fraction (A)
and the TBS/NP40-soluble “Soluble” fractions (B) of brain homogenates were analyzed by ELISA for A42 and A40. C, Brain
sections (n  6 for both the J20 and J20/A7 / groups) were stained with ThS and images were captured using fluorescence
microscopy. Scale bar, 500 m. D, ThS staining was quantified as number of plaques per hippocampal section. Data for J20 (n 
6) and J20/A7 / (n  6) mice are mean  SE (*p  0.05; **p  0.01). Note that the ELISA data are derived from hemibrain
homogenates (see Materials and Methods) that include the hippocampus and other brain regions.
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show that that these regional differences were observed clearly in
both the J20 and J20/A7/ mice (Fig. 4A,B). Moreover, when
each of these brain regions was analyzed separately, we found no
evidence for a change in apoE levels (Fig. 4C,D). This confirms
that ABCA7 deletion has no significant impact on cerebral apoE
levels.
ABCA7 deletion inhibits cellular uptake of A in vitro
Microglia and macrophages contribute to A degradation in the
brain (Bolmont et al., 2008; Thanopoulou et al., 2010; Cramer et
al., 2012). There is increasing evidence that bone marrow-derived
microglia (not resident microglia) play the major role in the
clearance of cerebral A (Malm et al., 2005; Simard et al., 2006;
Mildner et al., 2011; Naert and Rivest, 2012). Based on previous
studies showing that ABCA7 regulates phagocytic uptake of apo-
ptotic debris and latex beads in a variety of phagocytic cell types
(Iwamoto et al., 2006; Jehle et al., 2006), we examined the uptake
of A by bone marrow-derived macrophages derived from both
WT and Abca7/ mice. A was sonicated and incubated to
promote the formation of oligomers that resemble those detected
in the human brain (Shankar et al., 2008). Macrophages accumu-
lated A predominantly as dimeric and trimeric species (Fig. 5A).
ABCA7-deficient cells contained significantly less (51%) A (Fig.
5A,B). These results are consistent with the proposal that ABCA7
deletion reduces the capacity of phagocytes to clear A from the
brain.
Assessment of microglia and macrophage markers in
the brain
We next examined the levels of microglia and macrophage mark-
ers (Iba1 and Mac2, respectively) and their plaque distribution to
search for obvious functional differences that may be correlated
with altered phagocyte numbers or activation status in the
ABCA7-deficient AD setting. Iba1 microglial staining was abun-
dant in the brain and increased in the region of amyloid plaques
(Fig. 5C). Mac2-positive cells (representing bone marrow-
derived macrophages and a subset of activated microglia) were
relatively uncommon throughout the parenchyma, but were
clearly detected in association with amyloid plaques (Fig. 5C).
Confocal analysis indicated that Iba1-postive cells colocalized
with A in plaques, whereas Mac2-postive cells were found in the
vicinity of plaques but did not colocalize directly (Fig. 5C). Global
levels of Iba1 and Mac2 assessed by Western blotting of hemi-
brain homogenates were not significantly altered in J20/A7/
compared with J20 mice (Fig. 5D–F). Analysis of hippocampal
Iba-positive and Mac2-positive cells also indicated no significant
difference, although trends for increased levels were observed for
both markers in the ABCA7-deficient mice (Fig. 5E,F). Using
previously described quantitative methods (Teunissen et al.,
2002), we did not detect differences in the Iba1 or Mac2 plaque
association or A colocalization (H. Li and B. Garner, unpub-
lished observations). Overall, these data suggest that ABCA7 loss
does not induce an obvious difference in cerebral microglia/mac-
Figure 2. Spatial reference memory using the cheeseboard paradigm. A, Mean latency (av-
eraged across 3 trials per day) to find the food reward. B, Percentage of time spent in the target
zone during the probe trial. Time spent in the target zone due to chance (12.5%) is marked with
a broken line. Data for WT control (n  9), J20 (n  14), and J20/A7 / (n  11) mice are
mean  SE. *p  0.05 compared with WT.
Figure 3. Impact of ABCA7 deletion on brain protein expression. A, Brain homogenates
were probed for the proteins listed. Representative blots (n  4 samples for each group)
are shown. -Actin is used as a loading control. B, Integrated optical density for blots of
all samples (J20, n  14; J20/A7 /, n  11) is shown. Levels are expressed relative to
J20 mice and presented as mean  SE. ***p  0.0001 and #p  0.05 compared with J20
mice.
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rophage number even though their capacity to take up A in vitro
may be impaired.
Discussion
Our study provides the first evidence that cerebral A peptide
deposition and ThS-positive plaque load are increased when
ABCA7 is deleted in an AD mouse model. Even though the extent
of increase in insoluble A42 induced by ABCA7 deletion in J20
mice in the present study is similar to that observed when ABCA1
was deleted in APP23 and PDAPP AD mouse models (Kol-
damova et al., 2005; Wahrle et al., 2005), one crucial difference is
that the change in A level induced by ABCA7 deletion is inde-
pendent of alterations in apoE concentration. This implies that
ABCA7 and ABCA1 may have different functions in the brain,
particularly regarding apoE function and AD. The lack of differ-
ence in TBS/NP40-soluble A and CTF in the absence of
ABCA7 suggests that accelerated amyloidogenic processing of
APP probably does not account for the increased A detected in
gHCl-soluble fractions of brain homogenates and in ThS-
positive plaques. This finding is similar to the lack of impact that
ABCA1 deletion has on APP processing in several AD mouse
models (Hirsch-Reinshagen et al., 2005; Koldamova et al., 2005;
Wahrle et al., 2005).
The finding that ABCA7 deletion did not exacerbate cognitive
deficits in the J20 mice may be due to the fact that soluble A
levels were not significantly changed. In support of this idea, it
has been shown in APP23 mice that, although ABCA1 deficiency
increases insoluble A levels, it is the soluble oligomeric A spe-
cies that are the most correlated with cognitive impairment (Left-
erov et al., 2009). An alternative explanation could be due to the
J20 mice reaching a “floor effect” in the cheeseboard paradigm.
By chance, mice were shown to spend 12.5% of their time in the
target zone (i.e., no learned preference) during a previous probe
trial (Karl et al., 2012). In the present study, the J20 mice on
average spent 16.1% of their time in the target zone during the
probe trial; therefore it was difficult to detect any further impair-
ment in spatial memory in the J20/A7/ mice (which spent
14.0% of their time in the target zone).
Our data suggest that ABCA7 deletion appears to impair the
uptake of A in vitro (Fig. 5A). Alternative explanations for the
reduced level of A detected in ABCA7-deficient macrophages
could include alterations to intracellular A degradation or facil-
itation of A resecretion. Regardless of the potential for these
pathways to affect intracellular A metabolism, it is intriguing
that ABCA7 deletion was not associated with increased soluble
A in the J20/A7/ mouse brain (Fig. 1B). Previous studies have
highlighted the important role that microglia and macrophages
play in the phagocytic clearance of A deposited within amyloid
plaques in AD mouse models and in A42-immunized human
AD patients (for review, see Perry et al., 2010). It is possible that
ABCA7 deletion primarily modulates cerebral A homeostasis
via altered microglial/macrophage clearance of amyloid plaques
rather than soluble A species. Whether this is the pathway that
links the recently identified ABCA7 SNPs with increased AD risk
remains to be determined.
It would be worthwhile to investigate the impact that ABCA7
deletion has on the soluble A dimers, trimers, and other oligo-
meric A species in future studies because the ELISA methods we
used may not detect such pathogenic species of A (Mc Donald et
al., 2010; Benilova et al., 2012). In preliminary studies, we probed
the brain homogenates analyzed in this study for oligomeric
forms of A using Western blot and dot blot assays and a variety
of monoclonal antibodies, including WO2 and 4G8 (which rec-
ognize A) and A11 (which recognizes a generic epitope com-
mon to prefibrillar oligomers); however, we were unable to detect
clearly the abovementioned oligomeric A species (H. Li, B. Gar-
ner, unpublished observations). Although cerebral bone
marrow-derived macrophages clearly play a role in cerebral A
clearance, it would also be interesting to study the phagocytic
uptake of in vitro-derived oligomeric A complexes by ABCA7-
Figure 4. Impact of ABCA7 deletion on apoE expression in different brain regions. A, C, Brain
homogenates were prepared and TBS-soluble fractions were probed for apoE. Representative
blots (n4 or n6 samples for each group) are shown. -Actin was used as a loading control.
B, D, Integrated optical density for blots of all samples (J20, n  14; J20/A7 /, n  11) is
shown. Levels are expressed relative to hippocampus (B) or J20 mice (D) and are presented as
mean  SE. ***p  0.0001 compared with hippocampus.
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deficient resident microglia because there
may be subtle differences in the function
of these cells in the brain.
The J20 mice used in the present study
express a mutant form of human APP
bearing both the Swedish (K670N/
M671L) and the Indiana (V717F) muta-
tions (Mucke et al., 2000). In future
studies, it will be important to also assess
the modulation of A homeostasis in
additional amyloidogenic mouse models,
including those that have a more aggres-
sive pathology due to the transgenic ex-
pression of multiple mutant genes (e.g.,
the APP/PS1 and 3xTg-AD mice) (Mc
Donald et al., 2010; Romberg et al., 2011).
Because these mice typically display
plaque pathology earlier than the J20
mice, the impact that ABCA7 deletion has
on plaque development at earlier time
points could also be investigated. Simi-
larly, our present study does not exclude
the possibility that ABCA7 deletion may
alter cerebral apoE levels at earlier time
points.
The deletion of ABCA1 in mice im-
pairs apoE lipidation significantly, and
this has been shown to play a critical role
in the metabolism of A and apoE in the
brain (Wahrle et al., 2004; Jiang et al.,
2008). The fact that ABCA7 deletion does
not affect cerebral apoE levels may be in-
terpreted as evidence that ABCA7 does
not play a significant role in apoE lipida-
tion in the brain and, furthermore, that
the increased A deposition detected in
the absence of ABCA7 is not due to an
apoE deficiency. However, the data pro-
vided herein do not prove this idea di-
rectly. Microdialysis studies have been
used recently to characterize apoE in mu-
rine cerebral interstitial fluid (Fitz et al.,
2012), and this approach may be useful in
future studies to measure changes in apoE
lipid composition and A binding.
In summary, we have shown that
ABCA7 deletion is associated with a sig-
nificant increase in insoluble A in the
brain and that ABCA7-deficient macro-
phages have a reduced capacity to phago-
cytose A. Although there appears to be
no obvious change in cerebral microglial
or macrophage markers, it remains possi-
ble that “plaque clearance” is reduced in
the absence of ABCA7 and that, over the
lifespan, this could lead to a higher overall
A load in the brain.Figure 5. Impact of ABCA7 deletion on A phagocytosis and brain macrophage/microglial markers. A, Bone marrow-derived
macrophages from WT and Abca7 /  mice were incubated with 5 M A oligomers (left) for 45 min. Cells were rinsed and
lysates were probed for A uptake by Western blotting. -Actin was used as a loading control. B, Integrated optical density for the
Western blot is shown. Levels are expressed relative to WT mice and are mean  SE. **p  0.01 compared with J20. C, Hippocam-
pal sections were stained for A, Iba1, and Mac2. Images were collected using confocal microscopy and merged as indicated. Scale
bar, 50 m. D, Iba1 and Mac2 levels in brain homogenates were assessed by Western blotting. Representative blots (n  4
samples) are shown. -Actin was used as a loading control. E, Iba1 and Mac2 in hippocampal sections were assessed by immu-
nohistochemistry. Scale bars: Top, 500 m; bottom, 50 m. F, Quantification of Iba1 and Mac2 blots (Western, J20, n  14;
4
J20/A7 /, n  11) and immunohistochemistry (IHC, J20,
n  6; J20/A7 /, n  6) is shown. Levels are expressed
relative to J20 mice and are mean  SE.
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